Clinical Trials Browser

Phase 1/2 × Active not recruiting × Sorafenib × Clear all

NCT03247088 2025-12-15

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Phase 1/2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute